Retinoblastoma and mental retardation microdeletion syndrome: clinical characterization and molecular dissection using array CGH - PubMed (original) (raw)

Case Reports

doi: 10.1007/s10038-007-0151-4. Epub 2007 May 15.

C Speciale 1, C Pescucci 1, V Uliana 1, K Sampieri 1, M Bruttini 1, I Longo 1, S De Francesco 2, T Pramparo 3, O Zuffardi 3, R Frezzotti 4, A Acquaviva 5, T Hadjistilianou 2, A Renieri 6, F Mari 1

Affiliations

• PMID: 17502991
• DOI: 10.1007/s10038-007-0151-4

Case Reports

Retinoblastoma and mental retardation microdeletion syndrome: clinical characterization and molecular dissection using array CGH

R Caselli et al. J Hum Genet. 2007.

Abstract

We describe three patients with retinoblastoma, dysmorphic features and developmental delay. Patients 1 and 2 have high and broad forehead, deeply grooved philtrum, thick anteverted lobes and thick helix. Patient 1 also has dolicocephaly, sacral pit/dimple and toe crowding; patient 2 shows intrauterine growth retardation and short fifth toe. Both patients have partial agenesis of corpus callosum. Patient 3 has growth retardation, microcephaly, thick lower lip and micrognathia. Using array-comparative genomic hybridization (CGH), we identified a 13q14 de novo deletion in patients 1 and 2, while patient 3 had a 7q11.21 maternally inherited deletion, probably not related to the disease. Our results confirm that a distinct facial phenotype is related to a 13q14 deletion. Patients with retinoblastoma and malformations without a peculiar facial phenotype may have a different deletion syndrome or a casual association of mental retardation and retinoblastoma. Using array-CGH, we defined a critical region for mental retardation and dysmorphic features. We compared this deletion with a smaller one in a patient with retinoblastoma (case 4) and identified two distinct critical regions, containing 30 genes. Four genes appear to be good functional candidates for the neurological phenotype: NUFIP1 (nuclear fragile X mental retardation protein 1), HTR2A (serotonin receptor 2A), PCDH8 (prothocaderin 8) and PCDH17 (prothocaderin 17).

PubMed Disclaimer

Similar articles

• 13q Deletion Syndrome Involving RB1: Characterization of a New Minimal Critical Region for Psychomotor Delay.
  Privitera F, Calonaci A, Doddato G, Papa FT, Baldassarri M, Pinto AM, Mari F, Longo I, Caini M, Galimberti D, Hadjistilianou T, De Francesco S, Renieri A, Ariani F. Privitera F, et al. Genes (Basel). 2021 Aug 26;12(9):1318. doi: 10.3390/genes12091318. Genes (Basel). 2021. PMID: 34573300 Free PMC article.
• Dysmorphic phenotype and neurological impairment in 22 retinoblastoma patients with constitutional cytogenetic 13q deletion.
  Baud O, Cormier-Daire V, Lyonnet S, Desjardins L, Turleau C, Doz F. Baud O, et al. Clin Genet. 1999 Jun;55(6):478-82. doi: 10.1034/j.1399-0004.1999.550614.x. Clin Genet. 1999. PMID: 10450867
• Interstitial deletion 2p11.2-p12: report of a patient with mental retardation and review of the literature.
  Tzschach A, Graul-Neumann LM, Konrat K, Richter R, Ebert G, Ullmann R, Neitzel H. Tzschach A, et al. Am J Med Genet A. 2009 Feb;149A(2):242-5. doi: 10.1002/ajmg.a.32637. Am J Med Genet A. 2009. PMID: 19161151 Review.
• 6p subtelomere deletion with congenital glaucoma, severe mental retardation, and growth impairment.
  Nakane T, Kousuke N, Sonoko H, Yuko K, Sato H, Kubota T, Sugita K. Nakane T, et al. Pediatr Int. 2013 Jun;55(3):376-81. doi: 10.1111/j.1442-200X.2012.03729.x. Pediatr Int. 2013. PMID: 23782370 Review.

Cited by

• Protocadherin 17 functions as a tumor suppressor suppressing Wnt/β-catenin signaling and cell metastasis and is frequently methylated in breast cancer.
  Yin X, Xiang T, Mu J, Mao H, Li L, Huang X, Li C, Feng Y, Luo X, Wei Y, Peng W, Ren G, Tao Q. Yin X, et al. Oncotarget. 2016 Aug 9;7(32):51720-51732. doi: 10.18632/oncotarget.10102. Oncotarget. 2016. PMID: 27351130 Free PMC article.
• Fine mapping of whole RB1 gene deletions in retinoblastoma patients confirms PCDH8 as a candidate gene for psychomotor delay.
  Castéra L, Dehainault C, Michaux D, Lumbroso-Le Rouic L, Aerts I, Doz F, Pelet A, Couturier J, Stoppa-Lyonnet D, Gauthier-Villars M, Houdayer C. Castéra L, et al. Eur J Hum Genet. 2013 Apr;21(4):460-4. doi: 10.1038/ejhg.2012.186. Epub 2012 Aug 22. Eur J Hum Genet. 2013. PMID: 22909775 Free PMC article.
• Screening for large rearrangements of the RB1 gene in Iranian patients with retinoblastoma using multiplex ligation-dependent probe amplification.
  Ahani A, Akbari MT, Saliminejad K, Behnam B, Akhondi MM, Vosoogh P, Ghassemi F, Naseripour M, Bahoush G, Khorshid HR. Ahani A, et al. Mol Vis. 2013;19:454-62. Epub 2013 Feb 22. Mol Vis. 2013. PMID: 23441118 Free PMC article.
• MECP2 Duplication Syndrome: Evidence of Enhanced Oxidative Stress. A Comparison with Rett Syndrome.
  Signorini C, De Felice C, Leoncini S, Møller RS, Zollo G, Buoni S, Cortelazzo A, Guerranti R, Durand T, Ciccoli L, D'Esposito M, Ravn K, Hayek J. Signorini C, et al. PLoS One. 2016 Mar 1;11(3):e0150101. doi: 10.1371/journal.pone.0150101. eCollection 2016. PLoS One. 2016. PMID: 26930212 Free PMC article.
• Retinoblastoma and polydactyly in a child with 46, XY, 15pstk+ karyotype-A case report and literature review.
  Pi X, Zhang Q, Wang X, Jiang F. Pi X, et al. Mol Genet Genomic Med. 2024 Mar;12(3):e2414. doi: 10.1002/mgg3.2414. Mol Genet Genomic Med. 2024. PMID: 38465842 Free PMC article. Review.

References

1. 1. Hum Genet. 1983;64(2):160-2 - PubMed
2. 1. Exp Cell Res. 2003 Sep 10;289(1):95-107 - PubMed
3. 1. J Med Genet. 1987 Nov;24(11):696-7 - PubMed
4. 1. Oncogene. 1992 Jul;7(7):1445-51 - PubMed
5. 1. Am J Med Genet. 1991 May 1;39(2):196-200 - PubMed

Publication types

MeSH terms

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program